Similar results were previously observed, showing that recurrent implantation failure patients with MetS (RIF-MS) decreased SOD and CAT levels in comparison with a control group, whereas the MPO levels increased in the MetS group [16]. The gene discussed is SOD1; the disease is metabolic syndrome.